Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Advanced Clear Cell Renal Cell Carcinoma
NCT04846920Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belzutifan in clear cell renal cell carcinoma (ccRCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experience at Least One Adverse Event (AE) at 49.5 months, Percentage of Participants Who Discontinue Study Treatment Due to an AE at 48.5 months and 2 more. Started Jun 2021; status: completed.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04846920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846920.